NALTREXONE IN AUTISTIC-CHILDREN - BEHAVIORAL SYMPTOMS AND ATTENTIONAL LEARNING

被引:122
作者
CAMPBELL, M
ANDERSON, LT
SMALL, AM
ADAMS, P
GONZALEZ, NM
ERNST, M
机构
[1] COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032
[2] CORNELL UNIV,MED CTR,NEW YORK HOSP,COLL MED,WESTCHESTER DIV,NEW YORK,NY 10021
[3] NIMH,ADAMHA,WASHINGTON,DC 20032
关键词
NALTREXONE; AUTISM; DISCRIMINATION LEARNING; SELF-INJURIOUS BEHAVIOR;
D O I
10.1097/00004583-199311000-00024
中图分类号
B844 [发展心理学(人类心理学)];
学科分类号
040202 ;
摘要
Objective: To assess critically the short-term efficacy and safety of naltrexone in autistic children and its effects on discrimination learning in the laboratory. Method: A parallel group design was employed. After a 2-week placebo baseline period, children were randomly assigned either to naltrexone or to placebo for a period of 3 weeks followed by a one-week posttreatment placebo period. Multiple raters and rating scales were employed in a variety of conditions. Forty-one children, all inpatients, ages 2.9 to 7.8 years, completed the study. Naltrexone reduced hyperactivity and had no effect on discrimination learning in the laboratory. There was a suggestion that it had a beneficial effect on decreasing self-injurious behavior. Untoward effects were mild and transient. Conclusion: In the present study, naltrexone significantly reduced only hyperactivity, and no serious untoward effects were observed. The effectiveness of naltrexone in the treatment of autism and self-injurious behavior requires additional assessment in a sample of children with moderate to severe self-injurious behavior.
引用
收藏
页码:1283 / 1291
页数:9
相关论文
共 46 条
[1]  
ANDERSON LT, 1984, AM J PSYCHIAT, V141, P1195
[2]   THE EFFECTS OF HALOPERIDOL ON DISCRIMINATION-LEARNING AND BEHAVIORAL SYMPTOMS IN AUTISTIC-CHILDREN [J].
ANDERSON, LT ;
CAMPBELL, M ;
ADAMS, P ;
SMALL, AM ;
PERRY, R ;
SHELL, J .
JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 1989, 19 (02) :227-239
[3]  
BARRETT RP, 1989, AM J MENT RETARD, V93, P644
[4]  
CAMPBELL M, 1985, PSYCHOPHARMACOL BULL, V21, P1047
[5]   NALTREXONE IN AUTISTIC-CHILDREN - AN ACUTE OPEN DOSE RANGE TOLERANCE TRIAL [J].
CAMPBELL, M ;
OVERALL, JE ;
SMALL, AM ;
SOKOL, MS ;
SPENCER, EK ;
ADAMS, P ;
FOLTZ, RL ;
MONTI, KM ;
PERRY, R ;
NOBLER, M ;
ROBERTS, E .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1989, 28 (02) :200-206
[6]   EFFICACY AND SAFETY OF FENFLURAMINE IN AUTISTIC-CHILDREN [J].
CAMPBELL, M ;
ADAMS, P ;
SMALL, AM ;
CURREN, EL ;
OVERALL, JE ;
ANDERSON, LT ;
LYNCH, N ;
PERRY, R .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1988, 27 (04) :434-439
[7]   COMPARISON OF HALOPERIDOL AND BEHAVIOR-THERAPY AND THEIR INTERACTION IN AUTISTIC-CHILDREN [J].
CAMPBELL, M ;
ANDERSON, LT ;
MEIER, M ;
COHEN, IL ;
SMALL, AM ;
SAMIT, C ;
SACHAR, EJ .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1978, 17 (04) :640-655
[8]   THE EFFECTS OF HALOPERIDOL ON LEARNING AND BEHAVIOR IN AUTISTIC-CHILDREN [J].
CAMPBELL, M ;
ANDERSON, LT ;
SMALL, AM ;
PERRY, R ;
GREEN, WH ;
CAPLAN, R .
JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 1982, 12 (02) :167-175
[9]  
CAMPBELL M, 1985, PSYCHOPHARMACOL BULL, V21, P1082
[10]   NEUROLEPTIC-INDUCED DYSKINESIAS IN CHILDREN [J].
CAMPBELL, M ;
GREGA, DM ;
GREEN, WH ;
BENNETT, WG .
CLINICAL NEUROPHARMACOLOGY, 1983, 6 (03) :207-222